Fortis Healthcare continues its positive momentum in Q2 FY25

Fortis Healthcare announced financial results for the second quarter of the 2025 financial year.

Q2FY25 consolidated revenues jumped 12.3% to Rs 1,988 crore as compared to Rs 1,770 in Q2FY24.

PAT increased 5% to Rs 193 crore in Q2FY25 as compared to Rs 184 crore in Q2FY24.

Operating EBITDA jumped 31.9% to Rs 435 crore in Q2FY25 as compared to Rs 330 crore in Q2FY24.

H1FY25 highlights
H1FY25 consolidated revenues jumped 12.3% to 3,847 crore as compared to Rs 3,427 in H1FY24.

PAT increased 19.2% to Rs 367 crore in H1FY25 as compared to Rs 308 crore in H1FY24.

Operating EBITDA jumped 29% to Rs 777 crore in H1FY25 as compared to Rs 603 crore in H1FY24.

“We have continued our positive momentum in Q2 with the hospital business contributing approximately 82% to our consolidated EBITDA. We are making good progress on our plans to add nearly 700 beds this fiscal year across key facilities, including Faridabad, Anandpur, Shalimar Bagh, and Noida. Commensurate with our expansion plans, our 350-bed Manesar facility which we acquired in FY24 was commissioned recently. Leveraging our robust balance sheet, we would actively pursue further inorganic growth opportunities in our focus geographic clusters,” said Dr. Ashutosh Raghuvanshi, MD and CEO, Fortis Healthcare.

“Among our key specialties, Oncology and Neuro Sciences grew by a strong 19% and 17%, respectively, compared to the same period last year. As part of our ongoing efforts to enhance our medical infrastructure, FMRI introduced the first MR LINAC in North and Central India in September. On the diagnostics business, we are moving ahead to consolidate our stake in Agilus by acquiring the 31.52% stake from the PE investors. The diagnostics business performance is witnessing a steady recovery with relatively improving topline growth and better EBITDA margins. However, the business is still impacted by rebranding expenses which we expect will taper off towards the end of the fiscal,” he added.
MB Bureau